Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues
暂无分享,去创建一个
R. Flavell | J. Wilson | R. Schilz | I. Grewal | Y. Yang | Q. Su | Yiping Yang | IQBAL S. Grewal | Y. Yang | Y. Yang | James M. Wilson | R. A. Flavell | Robert Schilz | SU Qin
[1] J. Wilson,et al. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. , 1996, Gene therapy.
[2] J. Suttles,et al. Impaired T cell-mediated macrophage activation in CD40 ligand-deficient mice. , 1996, Journal of immunology.
[3] D. Gray,et al. CD40 ligand-transduced co-stimulation of T cells in the development of helper function , 1995, Nature.
[4] R. Flavell,et al. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand , 1995, Nature.
[5] H. Griesser,et al. Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.
[6] J. Bluestone,et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.
[7] A. Gown,et al. Long–term hepatic adenovirus–mediated gene expression in mice following CTLA4Ig administration , 1995, Nature Genetics.
[8] G. Trinchieri,et al. Recombinant IL–12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung , 1995, Nature Medicine.
[9] M. Kay,et al. Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. , 1995, Human gene therapy.
[10] Z. Xiang,et al. Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[11] J. Mcghee,et al. Intratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA antibodies to adenovirus and beta-galactosidase. , 1995, Human gene therapy.
[12] H. Ertl,et al. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses , 1995, Journal of virology.
[13] J. Whitsett,et al. Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu/nu) mice. , 1995, Human gene therapy.
[14] N. Sarvetnick,et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[15] R J Armitage,et al. Humoral immune responses in CD40 ligand-deficient mice , 1994, The Journal of experimental medicine.
[16] R. Noelle,et al. The role of CD40 in the regulation of humoral and cell-mediated immunity. , 1994, Immunology today.
[17] M. Jenkins. The ups and downs of T cell costimulation. , 1994, Immunity.
[18] R. Flavell,et al. Mice deficient for the CD40 ligand. , 1994, Immunity.
[19] H. Ertl,et al. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. , 1994, Immunity.
[20] James M. Wilson,et al. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis , 1994, Nature Genetics.
[21] A. Aruffo,et al. gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory , 1994, The Journal of experimental medicine.
[22] J. Wilson,et al. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[23] N. Yoshida,et al. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. , 1994, Immunity.
[24] E. Furth,et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[25] J. Wilson,et al. In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. , 1994, The Journal of biological chemistry.
[26] B. Trapnell,et al. Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung. , 1994, Gene therapy.
[27] A. Aruffo,et al. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. , 1993, Science.
[28] M. Kay,et al. Assessment of recombinant adenoviral vectors for hepatic gene therapy. , 1993, Human gene therapy.
[29] J. Belmont,et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome , 1993, Science.
[30] A. Fischer,et al. CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM , 1993, Nature.
[31] L. Notarangelo,et al. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM , 1993, Nature.
[32] J. Bajorath,et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome , 1993, Cell.
[33] M. Perricaudet,et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium , 1992, Cell.
[34] J. Wilson,et al. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. , 1996, Gene therapy.
[35] J. Suttles,et al. Impaired T cell-mediated macrophage activation in CD40 ligand-deficient mice. , 1996, Journal of immunology.
[36] D. Gray,et al. CD40 ligand-transduced co-stimulation of T cells in the development of helper function , 1995, Nature.
[37] R. Flavell,et al. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand , 1995, Nature.
[38] H. Griesser,et al. Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.
[39] J. Bluestone,et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.
[40] A. Gown,et al. Long–term hepatic adenovirus–mediated gene expression in mice following CTLA4Ig administration , 1995, Nature Genetics.
[41] G. Trinchieri,et al. Recombinant IL–12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung , 1995, Nature Medicine.
[42] M. Kay,et al. Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. , 1995, Human gene therapy.
[43] Z. Xiang,et al. Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[44] J. Mcghee,et al. Intratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA antibodies to adenovirus and beta-galactosidase. , 1995, Human gene therapy.
[45] H. Ertl,et al. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses , 1995, Journal of virology.
[46] J. Whitsett,et al. Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu/nu) mice. , 1995, Human gene therapy.
[47] N. Sarvetnick,et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[48] R J Armitage,et al. Humoral immune responses in CD40 ligand-deficient mice , 1994, The Journal of experimental medicine.
[49] R. Noelle,et al. The role of CD40 in the regulation of humoral and cell-mediated immunity. , 1994, Immunology today.
[50] M. Jenkins. The ups and downs of T cell costimulation. , 1994, Immunity.
[51] R. Flavell,et al. Mice deficient for the CD40 ligand. , 1994, Immunity.
[52] H. Ertl,et al. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. , 1994, Immunity.
[53] Andrew H. Liu,et al. CD40 LIGAND MUTATIONS IN X-LINKED IMMUNODEFICIENCY WITH HYPER-IgM , 1994, Pediatrics.
[54] James M. Wilson,et al. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis , 1994, Nature Genetics.
[55] A. Aruffo,et al. gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory , 1994, The Journal of experimental medicine.
[56] J. Wilson,et al. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[57] N. Yoshida,et al. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. , 1994, Immunity.
[58] E. Furth,et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[59] J. Wilson,et al. In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. , 1994, The Journal of biological chemistry.
[60] B. Trapnell,et al. Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung. , 1994, Gene therapy.
[61] A. Aruffo,et al. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. , 1993, Science.
[62] M. Kay,et al. Assessment of recombinant adenoviral vectors for hepatic gene therapy. , 1993, Human gene therapy.
[63] J. Belmont,et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome , 1993, Science.
[64] L. Notarangelo,et al. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM , 1993, Nature.
[65] J. Bajorath,et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome , 1993, Cell.
[66] M. Perricaudet,et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium , 1992, Cell.